11-108316031-A-T
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 2P and 0B. PM2_SupportingPM3_Supporting
This summary comes from the ClinGen Evidence Repository: The c.6116A>T variant in ATM is a missense variant predicted to cause substitution of glutamic acid by valine at amino acid 2039 (p.Glu2039Val). This variant has been detected in at least one individual with Ataxia-Telangiectasia (PMID:26896183). This variant is absent from gnomAD v2.1.1. The computational predictor REVEL gives a score of 0.429, which is neither above nor below the thresholds predicting a damaging or benign impact on ATM function. In summary, this variant meets criteria to be classified as a variant of uncertain significance for autosomal dominant ATM-related cancer predisposition and autosomal recessive Ataxia-Telangiectasia based on the ACMG/AMP criteria applied, as specified by the HBOP VCEP. (PM3_Supporting, PM2_Supporting) LINK:https://erepo.genome.network/evrepo/ui/classification/CA16616706/MONDO:0700270/020
Frequency
Consequence
NM_000051.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ATM | NM_000051.4 | c.6116A>T | p.Glu2039Val | missense_variant | 42/63 | ENST00000675843.1 | NP_000042.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ATM | ENST00000675843.1 | c.6116A>T | p.Glu2039Val | missense_variant | 42/63 | NM_000051.4 | ENSP00000501606.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1461850Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 727230
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Ataxia-telangiectasia syndrome Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jun 30, 2023 | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant disrupts the p.Glu2039 amino acid residue in ATM. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 19431188, 19781682, 22071889, 28975465). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. ClinVar contains an entry for this variant (Variation ID: 417621). This missense change has been observed in individuals with ataxia-telangiectasia (PMID: 26896183). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces glutamic acid, which is acidic and polar, with valine, which is neutral and non-polar, at codon 2039 of the ATM protein (p.Glu2039Val). - |
ATM-related cancer predisposition Uncertain:1
Uncertain significance, reviewed by expert panel | curation | ClinGen Hereditary Breast, Ovarian and Pancreatic Cancer Variant Curation Expert Panel, ClinGen | Nov 26, 2024 | The c.6116A>T variant in ATM is a missense variant predicted to cause substitution of glutamic acid by valine at amino acid 2039 (p.Glu2039Val). This variant has been detected in at least one individual with Ataxia-Telangiectasia (PMID: 26896183). This variant is absent from gnomAD v2.1.1. The computational predictor REVEL gives a score of 0.429, which is neither above nor below the thresholds predicting a damaging or benign impact on ATM function. In summary, this variant meets criteria to be classified as a variant of uncertain significance for autosomal dominant ATM-related cancer predisposition and autosomal recessive Ataxia-Telangiectasia based on the ACMG/AMP criteria applied, as specified by the HBOP VCEP. (PM3_Supporting, PM2_Supporting) - |
Familial cancer of breast Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Sanfordhealth-Fargo, Sanfordhealth | - | This VUS was reported by GeneDx 5/22/2015. VUS present in woman (pt A4 my pedigree) who had breast ca age 29 yrs. VUS also present in her mother who had breast ca age 51 years. Patient A4 has a maternal first cousin A7 who had colon cancer age 22 years and testicular cancer 22 years. Another individual C5 in maternal family had pancreatic cancer age 72 years. - |
Hereditary cancer-predisposing syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 06, 2019 | The p.E2039V variant (also known as c.6116A>T), located in coding exon 41 of the ATM gene, results from an A to T substitution at nucleotide position 6116. The glutamic acid at codon 2039 is replaced by valine, an amino acid with dissimilar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at